Background
==========

As immunosuppressive agents have continued to improve, the lifespans of recipients after renal transplantation have been prolonged. Unfortunately, immunosuppressed renal transplant patients have a higher incidence of carcinomas than the general population \[[@B1]-[@B3]\].

The treatment of breast cancer in the transplant population is somewhat complicated by factors such as determining the correct dose of immunosuppressant, survival of transplant grafts, and doses of adjuvant chemotherapy. However, there is limited information regarding the treatment of this disease. Although the number of cases was small, we sought to evaluate the nature and prognosis of post-transplant breast cancer (PTBC) and to suggest optimal strategies based on our experience and a review of the literature.

Methods
=======

Patient cohort
--------------

A total of 2,139 consecutive patients with chronic renal failure underwent kidney transplantation in our hospital between March 1999 and December 2011. All clinical and pathological features of the recipients of renal transplants were collected from the database of Seoul St. Mary's Hospital. Among these patients, 142 experienced post-transplant malignancy (PTM) and 11 were diagnosed with post-transplant breast cancer (PTBC). These 11 patients underwent operations between 1999 and 2011.

In the meantime, 2,554 patients were diagnosed with invasive breast cancer and underwent operations between 1999 and 2011. Exclusion criteria were patients with no pathological TNM status due to mass excision at an outside hospital, in situ breast cancer, previous breast cancer surgery, prior radiation, distant metastasis, and prior axillary surgery. Thus, in total, 1,722 patients were reviewed. All protocols were approved by the institutional review committee of Seoul St. Mary's Hospital, Catholic University of Korea (KC12RISI0626) and met the guidelines of the responsible governmental agency.

Statistical analyses
--------------------

The primary endpoint was death (overall survival). All patients who underwent an operation according to the standard protocols used at our hospital were treated with adjuvant chemotherapy and/or radiotherapy. Overall survival (OS) was defined as the time from the diagnosis of breast cancer to death. Statistical significance was determined using the chi-squared test. Survival rates were calculated by the Kaplan--Meier method and compared with the log-rank test, and then by stage of disease. *P* values \< 0.05 were deemed to indicate statistical significance.

Results
=======

Overall, 142 subjects experienced post-transplant malignancy (PTM; 6.6%). All cases were confirmed both clinically and histologically. Of the 142 PTM patients, 11 (0.5%) developed PTBC. These 11 patients underwent operations between 1999 and 2011. The mean ages of the PTM and PTBC cases were 54.7 ± 20.7 and 35 ± 8.0 years, respectively. The mean times before the occurrence of cancer were 110.7 ± 71.3 and 136.5 ± 101.2 months, respectively (Table [1](#T1){ref-type="table"}).

###### 

Comparison of demographics

                                                **KT**        **PTM**        **PTBC**
  --------------------------------------------- ------------- -------------- ---------------
  *n*                                           2,139         142            11
  Age, years (mean ± SD)                        51.0 ± 17.1   54.7 ± 20.7    35 ± 8.0
  Male: female ratio                            65.0 : 35.0   54.9 : 45.1    9.1 : 90.9
  Mean time of occurrence, months (mean ± SD)                 110.7 ± 71.3   136.5 ± 101.2

KT: kidney transplantation; PTBC: post-transplant breast cancer; PTM: post-transplant malignancy.

Of the 11 PTBC patients, 9 patients take 200 mgNeoral capsule(cyclosporine capsules) per day. One patient takes azathioprine (patient number 9) and one other patient takes FK506 (tacrolimus) (patient number 1).

Unlike other studies \[[@B4]-[@B7]\], gastrointestinal cancers, such as stomach and colon cancer, developed in 39 of the 142 PTM patients (27.5%) and were the most frequent. Other cancers were lymphomas (14.8%), urogenital cancers (12%), gynecological cancers (8.5%), and breast cancer (7.7%).

Table [2](#T2){ref-type="table"} shows the clinicopathological features of the 11 PTBC patients. The median age at diagnosis of breast cancer was 49 years. Five patients underwent modified radical mastectomies, four had simple mastectomies with sentinel lymph node biopsies, one had a wide excision with sentinel lymph node biopsy, and one underwent an excision biopsy only. Five patients received adjuvant chemotherapy and one, neoadjuvant chemotherapy. The stages were I for five, II for one, III for four, and unknown for one patient. Five underwent adjuvant endocrine therapy and two, radiation therapy. One experienced post-operative bleeding. After 30 months median follow-up, two have died.

###### 

Clinicopathological features of the 11 PTBC patients

  **Patient**   **Age**   **Duration to diagnosis** (**months**)   **Procedure**     **Stage**   **Positivity of hormone receptor**   **Type of chemotherapy**^**a**^   **Recurrence**      **Status**   **Follow**-**up duration** (**months**)
  ------------- --------- ---------------------------------------- ----------------- ----------- ------------------------------------ --------------------------------- ------------------- ------------ -----------------------------------------
  1             42        42                                       SM with SLNB      I           \+                                   \-                                \-                  Alive        127
  2             49        6                                        MRM               I           \+                                   \-                                \-                  Alive        119
  3             28        127                                      MRM               III         \-                                   CAF(×6)                           Bone, lung          Dead         95
  4             24        134                                      Excision biopsy   Unknown     \-                                   \-                                \-                  Alive        146
  5             40        177                                      SM with SLNB      I           \-                                   \-                                \-                  Alive        101
  6             43        181                                      MRM               III         \-                                   CMF(×6) + AT(×4)                  Bone, lung, liver   Dead         30
  7             35        89                                       MRM               III         \-                                   AC(×4) + T(×4)                    \-                  Alive        49
  8             28        354                                      SM with SLNB      II          \+                                   AC(×4)                            \-                  Alive        8
  9             29        176                                      WE with SLNB      I           \+                                   \-                                \-                  Alive        37
  10            29        208                                      SM with SLNB      I           \-                                   \-                                \-                  Alive        28
  11            38        8                                        MRM               III         \+                                   AC(×4)                            \-                  Alive        17

^a^C: cyclophosphamide, M: methotrexate, F: 5-fluorouracil, A: adriamycin, T: taxotere.

MRM: modified radical mastectomy; SLNB: sentinel lymph node biopsy;SM: simple mastectomy;WE: wide excision.

Figure [1](#F1){ref-type="fig"} shows stage-specific survival of 1,722 breast cancer patients who underwent breast surgery between 1999 and 2011 at our hospital. Five-year overall survival was 92.6%. Five-year survival for each stage was 97.7% for stage I, 92.9% for stage II, 78.6% for stage III, and 49.9% for stage IV. In our study, the median follow-up period for PTBC patients was 49 months (range: 8--146 months) and two of the 11 PTBC patients died, after 30 and 95 months of follow-up. Cumulative stage-specific survival for the general population of breast cancer patients was compared with the PTBC patients (Table [3](#T3){ref-type="table"}). Although based on a small number of cases, the 5-year survival for expected stage III-specific survival was 66.7% and no significant statistical difference was seen compared to that of the general population of breast cancer patients (*P* = 0.213).

![**Cumulative stage**-**specific survival of general population for breast cancer patients.** Five-year survival for each stage was 97.7% for stage I, 92.9% for stage II, 78.6% for stage III, and 49.9% for stage IV.](1477-7819-11-77-1){#F1}

###### 

**Comparison of cumulative stage**-**specific survival**

              **PTBC**^**a**^   **General population of breast cancer**^**a**^   ***P*value**
  ----------- ----------------- ------------------------------------------------ --------------
  Stage I     101.0 (28--127)   71.0 (6--163)                                    0.690
  Stage II    8.0 (8)           77.0 (3--163)                                    0.766
  Stage III   39.5 (17--95)     70.0 (8--161)                                    0.213

^a^Data are median months of survival with range in parentheses.

PTBC:post-transplant breast cancer.

Discussion
==========

Patients undergoing kidney transplantation have a higher risk of developing cancer as a result of immunosuppressive treatment \[[@B1],[@B3],[@B6]\]. Thus, there is the possibility that the population of breast cancer sufferers after kidney transplantation will increase. This is the first report to describe the characteristics of PTBC and to compare the incidence of breast cancer in PTBC patients with that in the general population.

Few reports have focused on breast cancer in the kidney transplant population. Vachtova et al. \[[@B8]\] reported PTBC without a reduction in the dose of immunosuppressive agent. However, this was a case report and one experience does not explain all patients. Popov et al. \[[@B5]\] and Veroux et al. \[[@B9]\] also reported one PTBC patient; however, they did not focus on the nature of the breast cancer and no description of the disease was provided. Thus, no comparison with the general population was made.

For treatingPTM, adjustment of the immunosuppressant agent(s) must be considered. The management of immunosuppression is also an area of concern because few data are available to guide decisions. When surgery is needed, dialysis access should be considered \[[@B10]\]. Renal graft function should be considered before chemotherapy. Among chemoagents, paclitaxel is an important treatment option in patients with impaired renal graft function \[[@B11]\]. There are few data regarding radiation or hormonal therapy.

A large cohort-based study reported that 5-year net survival was 84% in the US and 81% in Europe \[[@B12]\], but this was age-standardized net survival. Women had a 5-year overall survival (OS) of 94% for stage 0, 90% for stage I, 82% for stage II, 56.9% for stage III, and 19% for stage IV \[[@B13]\]. In our study, median follow-up was 68 months, and two of the 11 PTBC patients died, after 30 and 95 months, of follow-up. For stage III patients, the probability of surviving was approximately 66.7% at 5 years after diagnosis, comparable to that reported by Greif et al. \[[@B13]\].

The younger age of PTBC patients in our study is probably due to the small number of patients. When more patients are evaluated, the age of PTBC patients might increase. This is because the majority of breast cancer cases occur in women older than 50, with the highest incidence rate occurring between the ages of 70 and 75 years \[[@B14]\].

Agraharkar et al. \[[@B15]\] found that the relative risk of breast cancer in a post-transplant population was approximately 0.7 compared with that of the general population. This is consistent with our findings. Also, Buell et al. \[[@B16]\] demonstrated that immunosuppression may not increase the incidence, but may increase the biological aggressiveness of breast cancer. However, no adjustment of immunosuppression was made in our 11 patients and overall survival was comparable to that of general breast cancer patients.

The management of immunosuppression is an area of concern when a cancer is diagnosed. The overall amount of immunosuppression is a factor that may lead to an increased incidence of malignancies after renal transplantation \[[@B17]\]. Decreased or cessation of immunosuppression has been associated with remission of lymphoproliferative processes. However, data forthe therapeutic benefit of reducing immunosuppression in patients with solid tumors is anecdotal \[[@B10]\]. Moreover, in a previous report by Marcen et al. \[[@B18]\], cyclosporine therapy was not a risk factor for any type of malignancy.

This study has some limitations. First, the small numbers cannot provide a proxy for the whole PTBC population. Second, the median follow-up for PTBC was short. This was due to the fact that most PTM is reported late (median, 134 months) after transplantation. Finally, this was a retrospective study and several confounding factors were not considered.

However, this study is useful because it is a rare study on the prognosis of breast cancer patients after kidney transplantation. To our knowledge, there has been no previous research on the prognosis of PTBC patients. Also, we recommend that modifying dose of immunosuppressant after transplantation may not be necessary with regard to the breast cancer.

Conclusion
==========

In conclusion, PTBC patients did not exhibit a poorer prognosis than the general breast cancer population. Transplant physicians should screen post-transplant patients to identify cancers at an early stage. With regard to PTBC, the best approach is a combination of breast surgery, transplant surgery, and nephrology.

Abbreviations
=============

MRM: modified radical mastectomy; OS: overall survival; KT: kidney transplantation; PTBC: post-transplant breast cancer; PTM: post-transplant malignancy; SLNB: sentinel lymph node biopsy; SM: simple mastectomy; WE: wide excision.

Competing interests
===================

The authors have declared no conflicts of interest.

Authors' contributions
======================

HY Kwak contributed mainly in the design, literature review, and writing of the article. The data were collected and assembled by HY Kwak and BJ Chae. BJ Chae, JS Bae, and SS Jung gave valuable advice and edited the discussion. Both SS Jung and BJ Song provided administrative support. BJ Song has given final approval for the version to be published. All authors read and approved the final manuscript.

Acknowledgement
===============

None
